Amendments to the Claims

This listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (currently amended) A method of treating cancer in a human comprising administering to said human, in which such treatment is desired, a bcl-2 antisense oligonucleotide at a dose of 0.01 to 50 mg/kg daily in more than one one or more cycle of therapy, each cycle of therapy consisting of 3 to 9 days, wherein each cycle of therapy is separated by an interval of time wherein said human receives no bcl-2 antisense oligonucleotide, and wherein said interval of time comprises at least one day, and further comprising administering one or more cancer therapeutics.

2. (canceled)

- 3. (previously presented) The method of Claim 1, wherein the one or more cycles each cycle of therapy consist of 4 to 7 days.
- 4. (currently amended) The method as in any of Claims 1 or 3 comprising administering 4 to 9 mg/kg/day of the bcl-2 antisense oligonucleotide.
- 5. (currently amended) The method as any of Claims 1 or 3 comprising administering 5 to 7 mg/kg/day of the bcl-2 antisense oligonucleotide.
- 6. (canceled).
- 7. (original) The method of Claim 6 wherein administration of the cancer therapeutic follows administration of the bcl-2 antisense oligonucleotide.

Appl. No: 09/709,170

Amendment dated April 30, 2007

Reply to office action of Nov. 28, 2006

8. (original) The method of Claim 6 wherein administration of the cancer therapeutic

precedes administration of the bcl-2 antisense oligonucleotide.

9. (original) The method of Claim 6 wherein the cancer therapeutic is administered

concurrently with the bcl-2 antisense oligonucleotide.

10. (original) The method of Claim 6 wherein said cancer therapeutic is a chemoagent,

radiotherapeutic, immunotherapeutic, cancer vaccine, anti-angiogenic agent, cytokine,

gene therapeutic, or hormonal agent.

11. (original) The method of Claim 10, wherein said cancer therapeutic is a chemoagent,

and wherein said chemoagent is dacarbazine, docetaxel, paclitaxel, cisplatin, 5-

fluorouracil, doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan or

cytosine arabinoside (Ara-C).

12. (previously presented) The method of Claim 6 or Claim 10 wherein said cancer

therapeutic is administered at a dose which is below the effective dose when the cancer

therapeutic is administered without the bcl-2 antisense oligonucleotide.

13. (currently amended) The method as in any of Claims 1, 3 or 6, wherein said

administration is by oral, intravenous infusion, subcutaneous injection, intramuscular

injection, topical, depo injection, implantation, time-release mode, intracavitary,

intranasal, inhalation, intratumor, or intraocular administration.

14. (currently amended) The method as in any of Claims 1, 3 or 6, wherein said cancer

is a cancer of the hematopoietic system, skin, bone and soft tissue, reproductive system,

genitourinary system, breast, endocrine system, brain, central nervous system, peripheral

nervous system, kidney, lung, respiratory system, thorax, gastrointestinal and alimentary

canal, lymph nodes, pancreas, hepatobiliary system, or cancer of unknown primary site.

3

Appl. No: 09/709,170

Amendment dated April 30, 2007

Reply to office action of Nov. 28, 2006

15. (currently amended) The method of any of Claims 1, 3 or 6, wherein said cancer is

non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, colon carcinoma, rectal

carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, renal cell

carcinoma, heptoma, bile duct carcinoma, choriocarcinoma, cervical cancer, testicular

cancer, lung carcinoma, bladder carcinoma, melanoma, head and neck cancer or brain

cancer.

16. (currently amended) The method as in any of Claims 1, 3 or 6, wherein the antisense

oligonucleotide is from 10 to 40 bases in length and is complementary to the pre-mRNA

or mRNA of the bcl-2 gene.

17. (original) The method of Claim 16, wherein the antisense oligonucleotide comprises

at least two phosphorothioate linkages.

18. (previously presented) The method of Claim 17, wherein the antisense

oligonucleotide comprises the sequence TCTCCCAGCGTGCGCCAT (SEQ ID NO: 17).

19. (currently amended) The method of treating cancer in a human comprising

administering to said human, in which such treatment is desired, one or more

chemoagents and a bcl-2 antisense oligonucleotide, wherein the bcl-2 antisense

oligonucleotide is administered at a dose of 0.01 to 50 mg/kg/ daily in one or more more

than one cycle eyeles of therapy, each cycle consisting of 3 to 9 days, and

wherein each cycle of therapy is separated by an interval of time wherein said human

receives no bcl-2 antisense oligonucleotide, and wherein said interval of time comprises

at least one day, and

wherein the chemoagent is dacarbazine, docetaxel, paclitaxel, cisplatin, 5-fluorouracil,

doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan or cytosine

arabinoside (Ara-C), and wherein the chemoagent is administered at a dose which is

below the effective dose when the chemoagent is administered without the bcl-2

oligonucleotide.

4

Appl. No: 09/709,170

Amendment dated April 30, 2007

Reply to office action of Nov. 28, 2006

20. (previously presented) The method of Claim 19, wherein said chemoagent is

paclitaxel and said dose is 10 to 135 mg/m²/cycle.

21. (previously presented) The method of Claim 19, wherein said chemoagent is

docetaxel and said dose is 6 to 60mg/m²/cycle.

22. (previously presented) The method of Claim 19, wherein said chemoagent is

fludarabine and said dose is 2.5 to 25 $\text{mg/m}^2/\text{cycle}$.

23. (previously presented) The method of Claim 19, wherein said chemoagent is

irinotecan and said dose is 5 to 50 mg/m²/cycle.

24-28 (canceled)

29-33 (canceled)

5